Nano Group Ferro Group Stenting Control ANOVA, p value
No. enrolled patients 60 60 60 NA
Mean duration of the follow-up, months 54 ± 13 (95% CI: median 57, min 47, max 60) 49 ± 14 (95% CI: median 52, min 41, max 60) 56 ± 17 (95% CI: median 57, min 45, max 60) NS
Subset Stent proximal Pre-dilatation with balloon No preparation Stent proximal Pre-dilatation with balloon No preparation   NA
No. patients (%) n=6 (10.0%) n=9 (15.0%) n=45 (75.0%) n=7 (11.7%) n=11 (18.3%) n=42 (70.0%) n=60 (100%) NA
Patients lost to follow-up, no. (%) 1 (16.7%) 1 (11.1%) 11 (24.4%) 0 (0%) 1 (9.1%) 8 (17.8%) 9 (15.0%) NA
Event-free survival (all cause), no. (%) 6 (100%) 9 (100%) 24 (53.3%) 6 (85.7%) 10 (90.9%) 14 (33.3%) 34 (56.7%) NS*, <0.05#
Target lesion cardiac death, no. (%) 0 (0%) 0 (0%) 2 (4.4%) 0 (0%) 1 (9.1%) 2 (4.8%) 3 (5.0%) NS
Target vessel cardiac death, no (%) 1 (16.7%) 1 (11.1%) 2 (4.4%) 1 (14.3%) 2 (18.2%) 3 (7.1%) 7 (11.7%) NS*, <0.05#
Non-cardiac death, no. (%): •Stroke •Trauma •Cancer •Others   0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)   0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)   15 (33.3%) 3 (6.7%) 4 (8.9%) 6 (13.3%) 2 (4.4%)   1 (14.3%) 1 (14.3%) 0 (0%) 0 (0%) 0 (0%)   1 (9.1%) 0 (0%) 1 (9.1%) 0 (0%) 0 (0%)   17 (40.5%) 3 (7.1%) 4 (9.5%) 8 (19.0%) 2 (4.8%)   16 (26.7%) 6 (10.0%) 5 (8.3%) 4 (6.7%) 1 (1.7%) NS*, <0.05# for each variable
Target lesion myocardial infarction, no. (%) 0 (%) 0 (%) 2 (4.4%) 0 (0%) 1 (9.1%) 2 (4.8%) 4 (6.7%) NS
Target vessel myocardial infarction, no. (%) 1 (16.7%) 1 (11.1%) 5 (11.1%) 1 (14.3%) 2 (18.2%) 7 (16.7%) 10 (16.7%) NS
Target lesion revascularization (TLR), no. (%) 0 (0%) 0 (0%) 4 (8.9%) 0 (0%) 1 (9.1%) 4 (9.5%) 6 (10.0%) NS
Target vessel revascularization (TVR), no. (%) 1 (16.7%) 1 (11.1%) 8 (17.8%) 1 (14.3%) 2 (18.2%) 13 (30.9%) 14 (23.3%) NS
Thrombosis of culprit artery, no. (%)
•ARC definite thrombosis
0 (0%)

0 (0%)
0 (0%)

0 (0%)
2 (4.4%)

2 (4.4%)
0 (0%)

0 (0%)
1 (9.1%)

1 (9.1%)
3 (7.1%)

3 (7.1%)
6 (10.0%)

6 (10.0%)
NS
Newcomers with diabetes mellitus, no. (%)
•Insulin-dependent
2 (33.3%)

2 (33.3%)
2 (22.2%)

0 (10.0%)
4 (8.9%)

4 (8.9%)
6 (85.7%)

1 (14.3%)
3 (27.3%)

1 (9.1%)
10 (23.8%)

3 (7.1%)
12 (20.0%)

5 (8.3%)
NS*,

<0.05#
Newcomers with SYNTAX score ≥23, no. (%) 1 (16.7%) 1 (11.1%) 4 (8.9%) 0 (0%) 2 (18.2%) 9 (21.4%) 9 (15.0%) <0.05 FAC
NS - non-significant (p value>0.05). NA – non-available, or not applicable. FAC – for all comparisons
* - p value for difference between groups;
# - p value for difference between subset with no preparation of the target lesion and other subsets Continuous variables are expressed as mean ± SD. ARC –Academic Research Consortium. The definition of definite on-site thrombosis was tailored to the type of intervention
Table 3: Clinical follow-up (one event per patient) at 60 months (0-5 years) after intervention.